Search results
This ASCO guideline builds on important efforts to collate scientific information about clinical use of cannabis and cannabinoids and provide guidance for clinicians, adults with cancer, caregivers, researchers, and oncology institutions.
13 mar 2024 · Clinicians should recommend against use of cannabis and/or cannabinoids in place of cancer-directed treatment (Type: Informal consensus; Evidence quality: Very low; Strength of recommendation: Strong).
13 mar 2024 · PDF. In 2024, ASCO published a guideline on the use of cannabis and cannabinoids by adults with cancer. 1 The guideline provides strategies for open, nonjudgmental communication and also discusses evidence regarding cannabis and cannabinoids as cancer-directed therapy and for managing cancer symptoms and treatment side effects.
22 lut 2022 · To assess the efficacy, tolerability and safety of cannabis‐based medicines, including medical cannabis, for treating pain and other symptoms in adults with cancer.
6 mar 2023 · The MASCC panel recommends against the use of cannabinoids as an adjuvant analgesic for cancer pain and suggests that the potential risk of harm and adverse events be carefully considered for all cancer patients, particularly with treatment with a checkpoint inhibitor.
Cannabis and/or cannabinoids are one of several pharmacologic options for adults with cancer experiencing refractory nausea and vomiting despite optimal prophylaxis. For such individuals, the 2020 ASCO antiemetics guideline 2 recommends
We performed a systematic review of randomized cannabis cancer trials to establish a guideline for its use in pain and to summarize the risk of harm and adverse events when used for any indication in cancer patients.
